TARSUS PHARMACEUTICALS INC TARS
ASignal's systematic analysis rates TARS as Neutral.
Reflects the latest available analysis · analyzed Nov 11, 2026
The case on TARS
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (63.9% YoY)
- High gross margin (83.78%) indicating pricing power
- Positive free cash flow ($79.94M)
- Low debt-to-equity ratio (0.86x) with strong cash position
- Current ratio of 1.96x suggesting short-term financial stability
- Negative return on equity (-319.84%)
- Negative operating and net margins
- EV/EBITDA of -54.60x indicating unprofitability
- Forward P/E of 343.40x, extremely high valuation
- No Reddit sentiment data available
See the full verdict on TARS
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes TARS
Most investors never get a second opinion, let alone several. ASignal runs TARS past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.